Skip to content
value.today

Histogen Inc.

Total raised
$40 M
4 rounds on record
Latest round
$15 M
Aug 2016
First round on record
Dec 2007
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Histogen Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2016$15 MNo. 4$10 to $50 million

Histogen Inc.: Raise no. 4, Aug 2016

Investors in this round

47 investors had bought by the notice of Sep 18, 2019: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard Pascoe · Executive Officer, Director
  • Brian Satz · Director
  • David Crean · Director
  • Jonathan Jackson · Director
  • Stephen Chang · Director
  • Yizhuo Zhang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard Pascoe, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 18, 2019. Read the notice at the SEC.

equitySEC
Apr 2013$10 MNo. 3$10 to $50 million

Histogen Inc.: Raise no. 3, Apr 2013

Investors in this round

2 investors had bought by the notice of Jun 29, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gail Naughton · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gail Naughton, Ceo. Source: SEC Form D, newest notice filed Jun 29, 2015. Read the notice at the SEC.

equitySEC
Dec 2010$5 MNo. 2$2 to $10 million

Histogen Inc.: Raise no. 2, Dec 2010

Investors in this round

34 investors had bought by the notice of Jun 29, 2015: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gail Naughton · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gail Naughton, Ceo. Source: SEC Form D, newest notice filed Jun 29, 2015. Read the notice at the SEC.

equitySEC
Dec 2007$9 MNo. 1$2 to $10 million

Histogen Inc.: Raise no. 1, Dec 2007

Investors in this round

65 investors had bought by the notice of Jun 29, 2015: 65 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gail Naughton · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gail Naughton, Ceo. Source: SEC Form D, newest notice filed Jun 29, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Histogen Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2019).

    SEC Form D · Sep 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2019

That is all the official record says: Histogen Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Histogen Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 65 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Histogen Inc.
NameRoleNamed in
Richard PascoeExecutive officerSep 2019
Gail NaughtonExecutive officerAug 2016
Brian SatzDirectorSep 2019
David CreanDirectorSep 2019
Jonathan JacksonDirectorSep 2019
Richard PascoeDirectorSep 2019
Stephen ChangDirectorSep 2019
Yizhuo ZhangDirectorSep 2019
Gail NaughtonDirectorAug 2016